Academy of Managed Care Pharmacy Format: Relevance, Rigor, Regulation, and Realism  by O'Brien, Bernie J.
Volume 6 • Number 5 • 2003
V A L U E  I N  H E A L T H
© ISPOR 1098-3015/03/$15.00/501 501–502 501
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152003 ISPORSeptember/October 200365501502EditorialEditorialEditorial
Academy of Managed Care Pharmacy Format: Relevance, 
Rigor, Regulation, and Realism
Bernie J. O’Brien, PhD
McMaster University and Center for Evaluation of Medicines, St. Joseph’s Hospital, Hamilton, Ontario, Canada
The Task Force Report from the Foundation for
Managed Care Pharmacy (FMCP) in this issue of
the journal [1] offers an overview of the welcome
update of the Academy of Managed Care Phar-
macy (AMCP) Format for Formulary Submissions
(Version 2.0), which was published in October
2002 (available from http://www.fmcpnet.org).
Reﬂecting on the experience with the ﬁrst AMCP
Format, the report echoes many issues that will be
familiar to those developing guidance for clinical
and economic evidence reimbursement submissions
around the world. The challenge is how to get
relevant and rigorous evidence to managed care
formulary decision makers while navigating the
regulatory and commercial realities of the pharma-
ceutical marketplace.
It is widely understood that the typical placebo-
controlled trial evidence on safety and efﬁcacy that
is relevant for product licensing decisions is seldom-
adequate evidence for making decisions on reim-
bursement of new medicines. Consider our own
work on the cost-effectiveness of a new antiviral
drug (oseltamivir) for treatment of inﬂuenza [2].
The effectiveness and efﬁciency of this treatment
hinge on two key variables concerning the speciﬁ-
city of diagnosis and treatment: 1) what proportion
of patients presenting and treated with ﬂu-like
illness will have the inﬂuenza virus; and 2) what
proportion of patients will be treated beyond the
efﬁcacy window of 48 hours from symptom onset
when the virus is still replicating? Close to 70% of
patients in the registration trials were virus positive
[3,4] and an inclusion criterion was that symptom
duration was less than 48 hours. Hence a mixture
of usage—that according to the “label” and that
which is “off-label”—will determine the real-world
effectiveness and cost-effectiveness. It is this “leak-
age” of a medicine’s usage into nonindicated popu-
lations, where treatment effects may be diluted and
cost-effectiveness eroded, which is major cause of
concern [5].
The price for attempting to provide relevant
evidence of real-world cost-effectiveness, complete
with anticipated leakage, is that the AMCP Format
needs to tread carefully around the regulatory
guardians of the product label—the Food and Drug
Administration (FDA). In a bizarre piece of regula-
tory theater, a manufacturer cannot simply provide
an AMCP Format dossier to a managed-care organ-
ization in a submission for formulary listing; the ini-
tiation of such an exchange must be an “unsolicited
request” from the MCO for such a dossier. What
passes the solicitation test—“I may have some evi-
dence for you but the FDA will not let me tell you
what it is unless you ask me for it in a special way?”
Rather than regulating the rules of solicitation it
would be better to focus more energy on making
sure that the content of the reimbursement dossiers
is not misleading.
Cost-effectiveness modeling is an important com-
ponent of drug reimbursement submissions around
the world and with the AMCP Format. Modeling
is an unavoidable part of evidence synthesis as it
relates to economic questions [6]. The danger is that
a model can be a “black box” if the structure, data,
and assumptions are not clear and transparent. In
this regard the work of the ISPOR Task Force on
Good Research Practices–Modeling Studies is a use-
ful benchmark for starting to think about quality
and standards [7]. An important aspect of the
AMCP format is that the manufacturer is required
to submit a full electronic working copy of the
model. This makes it possible for a third party to
interrogate a model and further understand struc-
ture and assumptions. It also capitalizes on the
modular and ﬂexible nature of models such that
local data (e.g., demographics, prices) can be
substituted into the model to tailor it to local
circumstances.
A potential commercial boundary on trans-
parency arises from concerns about conﬁdentiality
of data and other evidence. The problem of how to
deal with commercial-in-conﬁdence data in cost-
effectiveness submissions is a thorny problem that is
not unique to US managed care but can also be
found in the assessments performed by the National
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Institute for Clinical Excellence (NICE) in the
United Kingdom [8]. Drummond has made the case
for full disclosure of all evidence for public scrutiny
in the context of NICE and makes convincing argu-
ments in favor of this view, particularly with respect
to the principle of decision transparency, such that
the evidence used for (for example) restricting ac-
cess to a medicine can be made known to patients
and providers. In contrast, the AMCP view appears
to be to encourage MCOs to ensure that conﬁden-
tiality of dossiers will be safeguarded. There is not
right or wrong here, just a difference of emphasis on
the needs of transparency versus the need to protect
property rights as a condition of the successful
exchange of information.
The report also contains a very important real-
ity check concerning human resources: faced with
increasingly sophisticated analyses and models,
MCOs as the recipients of this information may
lack the skilled labor to review and interpret the
submissions. Again this problem is echoed around
the world, particularly in countries such as Aus-
tralia, Canada, and the United Kingdom where
cost-effectiveness evidence supporting formulary
listing has been required for some years. Industry
can offer higher wages and attract a large share of
the skilled pool of labor in outcomes research and
cost-effectiveness. Part of the solution, as FMCP has
been quick to understand, is offering training work-
shops on how to use the AMCP format. But it may
also make good business sense for the pharmaceu-
tical industry to help subsidize the continuing edu-
cation of MCO dossier reviewers in contemporary
methods of modeling and cost-effectiveness. Help-
ing to create the skilled receptors in managed care
for the evidence and analyses submitted is almost as
important as the studies themselves.
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